Skip to main content
    A

    Amgen Inc (AMGN)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ

    $462.32
    -3.35 (-0.72%)

    Market Cap: $251.89B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Amgen Inc (AMGN) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Amgen (AMGN) trades at 19.9x trailing earnings and 6.4x sales. Its P/E of 19.9x is above its 5-year median of 14.7x. Its forward P/E is 19.1x. The median P/E across 9 similar companies is 21.4x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 4.2% higher over the next year. Its free cash flow yield is 3.8%.

    MultipleValue
    P/E (trailing)19.9x
    Forward P/E19.1x
    Price to sales6.4x
    Price to book17.4x
    EV/EBITDA16.0x
    Price to FCF26.1x
    EV/FCF30.4x
    PEG2.8
    FCF yield3.8%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 39.2% above 14.3x, its P/S is 20.8% above 5.3x and its P/B is 10.1% above 15.8x.

    MultipleCurrent5-year median10-year median
    P/E19.9x14.7x14.3x
    P/S6.4x5.1x5.3x
    P/B17.4x23.4x15.8x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 12.6x in 2016 to 16.3x in 2019.

    Year endPriceP/EP/SP/B
    2025$327.3115.0x4.8x20.5x
    2024$260.6413.2x4.2x24.0x
    2023$288.0215.4x5.5x25.0x
    2022$262.6414.8x5.4x38.7x
    2021$224.9713.1x4.9x19.0x
    2020$229.9213.9x5.3x14.3x
    2019$241.0716.3x6.3x14.9x
    2018$194.6713.5x5.4x10.0x
    2017$173.9013.8x5.6x5.0x
    2016$146.2112.6x4.8x3.7x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About AMGN

    What is AMGN's forward P/E ratio?

    Amgen has a forward P/E ratio of 19.1x.

    Is AMGN stock overvalued?

    GNG's valuation label for AMGN is Overvalued. Its P/E of 19.9x compares with a median of 21.4x across 9 similar companies.

    What is AMGN's price to sales ratio?

    Amgen has a price to sales ratio of 6.4x.

    What is Amgen's average P/E ratio over 5 years?

    Amgen's median P/E over the last 5 years is 14.7x, from 60 month-end values through Oct 2026.

    What is AMGN's PEG ratio?

    Amgen has a PEG ratio of 2.8.